Sulopenem Etzadroxil

CHEMBL4594246 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
477.6 g/mol
LogP
2.1
Phase
4

Sulopenem etzadroxil is an oral prodrug of the penem-class beta-lactam antibiotic sulopenem, used for the treatment of uncomplicated urinary tract infections including those caused by quinolone-resistant gram-negative bacteria. After oral absorption, the etzadroxil ester is cleaved to release sulopenem, which inhibits bacterial cell wall synthesis by irreversibly binding penicillin-binding proteins (PBPs), providing broad-spectrum activity including against ESBL-producing Enterobacteriaceae. It offers an important oral treatment option for resistant urinary tract infections.

Khối lượng phân tử

477,6000 g/mol

LogP

2,10

TPSA

180,00 Ų

Lipinski RO5

Đạt

Cơ chế tác dụng

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC(CC)C(=O)OCOC(=O)C1=C(S[C@H]2CC[S+]([O-])C2)S[C@@H]2[C@@H]([C@@H](C)O)C(=O)N12

InChI

InChI=1S/C19H27NO7S3/c1-4-11(5-2)17(23)26-9-27-18(24)14-19(28-12-6-7-30(25)8-12)29-16-13(10(3)21)15(22)20(14)16/h10-13,16,21H,4-9H2,1-3H3/t10-,12+,13+,16-,30?/m1/s1

Molecular Formula

C19H27NO7S3

HBD / HBA

1 / 10

Liên kết có thể quay

11

Nguyên tử nặng

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

Sulopenem etzadroxil is an oral prodrug of the penem-class beta-lactam antibiotic sulopenem, used for the treatment of uncomplicated urinary tract infections including those caused by quinolone-resistant gram-negative bacteria. After oral absorption, the etzadroxil ester is cleaved to release sulopenem, which inhibits bacterial cell wall synthesis by irreversibly binding penicillin-binding proteins (PBPs), providing broad-spectrum activity including against ESBL-producing Enterobacteriaceae. It offers an important oral treatment option for resistant urinary tract infections.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Sulopenem Etzadroxil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594246. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23642298. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.